Albany Molecular Research Inc., a drug developer with about 1,300 employees, has announced a plan to sell up to $50 million worth of its stock and related securities.
The homegrown public company (Nasdaq: AMRI) filed the proposal this week with the U.S. Securities and Exchange Commission.
AMRI described a broad range of potential plans for the money, including for capital expenditures, debt repayment and the acquisition of other companies or businesses, the filing shows. Company officials could not immediately be reached to comment on the Dec. 8 filing.
Hey, check out all the research scientist jobs. Post your resume today!
The homegrown public company (Nasdaq: AMRI) filed the proposal this week with the U.S. Securities and Exchange Commission.
AMRI described a broad range of potential plans for the money, including for capital expenditures, debt repayment and the acquisition of other companies or businesses, the filing shows. Company officials could not immediately be reached to comment on the Dec. 8 filing.
Hey, check out all the research scientist jobs. Post your resume today!
